ID   HYES_RAT                Reviewed;         554 AA.
AC   P80299;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   24-JUL-2024, entry version 161.
DE   RecName: Full=Bifunctional epoxide hydrolase 2 {ECO:0000305};
DE   Includes:
DE     RecName: Full=Cytosolic epoxide hydrolase 2;
DE              Short=CEH;
DE              EC=3.3.2.10 {ECO:0000269|PubMed:8626766};
DE     AltName: Full=Epoxide hydratase;
DE     AltName: Full=Soluble epoxide hydrolase;
DE              Short=SEH;
DE   Includes:
DE     RecName: Full=Lipid-phosphate phosphatase;
DE              EC=3.1.3.76 {ECO:0000305|PubMed:12574508};
GN   Name=Ephx2 {ECO:0000312|RGD:620732};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=8349641; DOI=10.1016/s0021-9258(19)85377-2;
RA   Knehr M., Thomas H., Arand M., Gebel T., Zeller H.-D., Oesch F.;
RT   "Isolation and characterization of a cDNA encoding rat liver cytosolic
RT   epoxide hydrolase and its functional expression in Escherichia coli.";
RL   J. Biol. Chem. 268:17623-17627(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 450-554, AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Liver;
RX   PubMed=1743286; DOI=10.1016/0014-5793(91)81333-4;
RA   Arand M., Knehr M., Thomas H., Zeller H.-D., Oesch F.;
RT   "An impaired peroxisomal targeting sequence leading to an unusual
RT   bicompartmental distribution of cytosolic epoxide hydrolase.";
RL   FEBS Lett. 294:19-22(1991).
RN   [3]
RP   FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-333; TRP-334; GLU-433;
RP   ASP-434; GLU-493; ASP-495; HIS-517; CYS-521; HIS-523; GLN-526; TRP-540 AND
RP   LYS-542, AND ACTIVE SITE.
RX   PubMed=8626766; DOI=10.1074/jbc.271.8.4223;
RA   Arand M., Wagner H., Oesch F.;
RT   "Asp333, Asp495, and His523 form the catalytic triad of rat soluble epoxide
RT   hydrolase.";
RL   J. Biol. Chem. 271:4223-4229(1996).
RN   [4]
RP   FUNCTION, PHOSPHATASE ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=12574508; DOI=10.1073/pnas.0437829100;
RA   Cronin A., Mowbray S., Durk H., Homburg S., Fleming I., Fisslthaler B.,
RA   Oesch F., Arand M.;
RT   "The N-terminal domain of mammalian soluble epoxide hydrolase is a
RT   phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:1552-1557(2003).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY
RP   REGULATION.
RX   PubMed=21217101; DOI=10.1194/jlr.m009639;
RA   Cronin A., Decker M., Arand M.;
RT   "Mammalian soluble epoxide hydrolase is identical to liver hepoxilin
RT   hydrolase.";
RL   J. Lipid Res. 52:712-719(2011).
CC   -!- FUNCTION: Bifunctional enzyme (PubMed:12574508, PubMed:8626766). The C-
CC       terminal domain has epoxide hydrolase activity and acts on epoxides
CC       (alkene oxides, oxiranes) and arene oxides (PubMed:8626766). Plays a
CC       role in xenobiotic metabolism by degrading potentially toxic epoxides
CC       (PubMed:8626766). Also determines steady-state levels of physiological
CC       mediators (By similarity). The N-terminal domain has lipid phosphatase
CC       activity, with the highest activity towards threo-9,10-phosphonooxy-
CC       hydroxy-octadecanoic acid, followed by erythro-9,10-phosphonooxy-
CC       hydroxy-octadecanoic acid, 12-phosphonooxy-octadec-9Z-enoic acid and
CC       12-phosphonooxy-octadec-9E-enoic acid (By similarity).
CC       {ECO:0000250|UniProtKB:P34913, ECO:0000269|PubMed:12574508,
CC       ECO:0000269|PubMed:8626766}.
CC   -!- FUNCTION: Bifunctional enzyme (PubMed:12574508, PubMed:8626766). The C-
CC       terminal domain has epoxide hydrolase activity and acts on epoxides
CC       (alkene oxides, oxiranes) and arene oxides (PubMed:8626766). Plays a
CC       role in xenobiotic metabolism by degrading potentially toxic epoxides
CC       (By similarity). Also determines steady-state levels of physiological
CC       mediators (By similarity). {ECO:0000250|UniProtKB:P34913,
CC       ECO:0000269|PubMed:8626766}.
CC   -!- FUNCTION: Bifunctional enzyme (PubMed:12574508, PubMed:8626766). The N-
CC       terminal domain has lipid phosphatase activity, with the highest
CC       activity towards threo-9,10-phosphonooxy-hydroxy-octadecanoic acid,
CC       followed by erythro-9,10-phosphonooxy-hydroxy-octadecanoic acid, 12-
CC       phosphonooxy-octadec-9Z-enoic acid and 12-phosphonooxy-octadec-9E-enoic
CC       acid (PubMed:12574508). Has phosphatase activity toward lyso-
CC       glycerophospholipids with also some lower activity toward lysolipids of
CC       sphingolipid and isoprenoid phosphates (By similarity).
CC       {ECO:0000250|UniProtKB:P34913, ECO:0000269|PubMed:12574508}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an epoxide + H2O = an ethanediol; Xref=Rhea:RHEA:19037,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:32955, ChEBI:CHEBI:140594;
CC         EC=3.3.2.10; Evidence={ECO:0000269|PubMed:8626766};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9S,10S)-10-hydroxy-9-(phosphooxy)octadecanoate + H2O =
CC         (9S,10S)-9,10-dihydroxyoctadecanoate + phosphate;
CC         Xref=Rhea:RHEA:16537, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:58796, ChEBI:CHEBI:58797; EC=3.1.3.76;
CC         Evidence={ECO:0000305|PubMed:12574508};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=8-hydroxy-(11S,12S)-epoxy-(5Z,9E,14Z)-eicosatrienoate + H2O =
CC         (8,11R,12S)-trihydroxy-(5Z,9E,14Z)-eicosatrienoate;
CC         Xref=Rhea:RHEA:50896, ChEBI:CHEBI:15377, ChEBI:CHEBI:78100,
CC         ChEBI:CHEBI:132127; Evidence={ECO:0000269|PubMed:21217101};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50897;
CC         Evidence={ECO:0000269|PubMed:21217101};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=10-hydroxy-(11S,12S)-epoxy- (5Z,8Z,14Z)-eicosatrienoate + H2O
CC         = (10,11S,12R)-trihydroxy-(5Z,8Z,14Z)-eicosatrienoate;
CC         Xref=Rhea:RHEA:50900, ChEBI:CHEBI:15377, ChEBI:CHEBI:78084,
CC         ChEBI:CHEBI:78099; Evidence={ECO:0000269|PubMed:21217101};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50901;
CC         Evidence={ECO:0000269|PubMed:21217101};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=12-phosphooxy-(9Z)-octadecenoate + H2O = 12-hydroxy-(9Z)-
CC         octadecenoate + phosphate; Xref=Rhea:RHEA:45272, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:85141, ChEBI:CHEBI:85150;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45273;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=12-phosphooxy-(9E)-octadecenoate + H2O = 12-hydroxy-(9E)-
CC         octadecenoate + phosphate; Xref=Rhea:RHEA:45276, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:85137, ChEBI:CHEBI:85152;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45277;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=12-(phosphooxy)octadecanoate + H2O = 12-hydroxyoctadecanoate +
CC         phosphate; Xref=Rhea:RHEA:45280, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:84201, ChEBI:CHEBI:85134;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45281;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate + H2O = 8,9-dihydroxy-
CC         (5Z,11Z,14Z)-eicosatrienoate; Xref=Rhea:RHEA:44048,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:84025, ChEBI:CHEBI:84032;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44049;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H2O = 11,12-
CC         dihydroxy-(5Z,8Z,14Z)-eicosatrienoate; Xref=Rhea:RHEA:44044,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:76625, ChEBI:CHEBI:84031;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44045;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=14,15-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H2O = 14,15-
CC         dihydroxy-(5Z,8Z,11Z)-eicosatrienoate; Xref=Rhea:RHEA:44040,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:84024, ChEBI:CHEBI:84029;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44041;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=9,10-epoxy-(12Z)-octadecenoate + H2O = 9,10-dihydroxy-(12Z)-
CC         octadecenoate; Xref=Rhea:RHEA:44032, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:84023, ChEBI:CHEBI:84027;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44033;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-tetradecanoyl-sn-glycerol 3-phosphate + H2O = 1-
CC         tetradecanoyl-sn-glycerol + phosphate; Xref=Rhea:RHEA:53592,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:72683,
CC         ChEBI:CHEBI:75536; Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53593;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-sn-glycero-3-phosphate + H2O = 1-octadecanoyl-
CC         sn-glycerol + phosphate; Xref=Rhea:RHEA:53596, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:74565, ChEBI:CHEBI:75550;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53597;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphate +
CC         H2O = 1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol + phosphate;
CC         Xref=Rhea:RHEA:53600, ChEBI:CHEBI:15377, ChEBI:CHEBI:34071,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:74938;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53601;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphate + H2O = 1-hexadecanoyl-
CC         sn-glycerol + phosphate; Xref=Rhea:RHEA:53604, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:57518, ChEBI:CHEBI:75542;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53605;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 1-(9Z-
CC         octadecenoyl)-sn-glycerol + phosphate; Xref=Rhea:RHEA:39835,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:74544,
CC         ChEBI:CHEBI:75757; Evidence={ECO:0000250|UniProtKB:P34913};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39836;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(8S,9R)-epoxy-(5Z,11Z,14Z)-eicosatrienoate + H2O = (8S,9S)-
CC         dihydroxy-(5Z,11Z,14Z)-eicosatrienoate; Xref=Rhea:RHEA:53972,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:131974, ChEBI:CHEBI:138002;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53973;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(11S,12R)-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H2O = (11R,12R)-
CC         dihydroxy-(5Z,8Z,14Z)-eicosatrienoate; Xref=Rhea:RHEA:53980,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:131969, ChEBI:CHEBI:138004;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53981;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(11S,12R)-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H2O = (11S,12S)-
CC         dihydroxy-(5Z,8Z,14Z)-eicosatrienoate; Xref=Rhea:RHEA:53984,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:131969, ChEBI:CHEBI:138005;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53985;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(14S,15R)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H2O = (14R,15R)-
CC         dihydroxy-(5Z,8Z,11Z)-eicosatrienoate; Xref=Rhea:RHEA:53992,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:131964, ChEBI:CHEBI:138003;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53993;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(14S,15R)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H2O = (14S,15S)-
CC         dihydroxy-(5Z,8Z,11Z)-eicosatrienoate; Xref=Rhea:RHEA:53996,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:131964, ChEBI:CHEBI:138006;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53997;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(11R,12S)-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H2O = (11S,12S)-
CC         dihydroxy-(5Z,8Z,14Z)-eicosatrienoate; Xref=Rhea:RHEA:54004,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:131970, ChEBI:CHEBI:138005;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54005;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(11R,12S)-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H2O = (11R,12R)-
CC         dihydroxy-(5Z,8Z,14Z)-eicosatrienoate; Xref=Rhea:RHEA:54000,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:131970, ChEBI:CHEBI:138004;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54001;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(8S,9R)-epoxy-(5Z,11Z,14Z)-eicosatrienoate + H2O = (8R,9R)-
CC         dihydroxy-(5Z,11Z,14Z)-eicosatrienoate; Xref=Rhea:RHEA:54016,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:131974, ChEBI:CHEBI:138008;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54017;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(14R,15S)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H2O = (14R,15R)-
CC         dihydroxy-(5Z,8Z,11Z)-eicosatrienoate; Xref=Rhea:RHEA:53976,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:131965, ChEBI:CHEBI:138003;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53977;
CC         Evidence={ECO:0000250|UniProtKB:P34914};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P34913};
CC   -!- ACTIVITY REGULATION: Inhibited by 1-(1-acetylpiperidin-4-yl)-3-(4-
CC       (trifl uoromethoxy)phenyl)urea (TPAU), 1-cyclohexyl-3-dodecylurea
CC       (CDU), 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), 1-((3S, 5S,
CC       7S)-adamantan-1-yl)-3-(5-(2-(2-ethoxyethoxy) ethoxy)pentyl)urea (AEPU),
CC       N-adamantyl-N[']-cyclohexyl urea (ACU), 4-(((1S, 4S)-4-(3-((3S, 5S,
CC       7S)-adamantan-1-yl) ureido)cyclohexyl)oxy)benzoic acid (c-AUCB), 4-
CC       (((1R, 4R)-4-(3-((3S, 5S, 7S)-adamantan-1-
CC       yl)ureido)cyclohexyl)oxy)benzoic acid (t-AUCB), 4-(((1R, 4R)-4-(3-
CC       (4(trifluoromethoxy)phenyl)ureido)cyclohexyl)oxy)benzoic acid (t-TAUCB)
CC       and to a lesser extent by 8-(3-((3S, 5S, 7S)-adamantan-1-yl)ureido)
CC       octanoic acid (AUOA) (PubMed:21217101). Phosphatase activity is
CC       inhibited by dodecyl-phosphate, phospholipids such as phospho-
CC       lysophosphatidic acids and fatty acids such as palmitic acid and lauric
CC       acid (By similarity). {ECO:0000250|UniProtKB:P34913,
CC       ECO:0000269|PubMed:21217101}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.235 mM for p-nitrophenyl phosphate
CC         {ECO:0000269|PubMed:12574508};
CC         KM=4.6 uM for 8-hydroxy-(11S,12S)-epoxy-(5Z,9E,14Z)-eicosatrienoate
CC         {ECO:0000269|PubMed:21217101};
CC         KM=14.7 uM for 10-hydroxy-(11S,12S)-epoxy- (5Z,8Z,14Z)-
CC         eicosatrienoate {ECO:0000269|PubMed:21217101};
CC         Vmax=1450 nmol/min/mg enzyme {ECO:0000269|PubMed:12574508};
CC         Vmax=1739 nmol/min/mg enzyme with 8-hydroxy-(11S,12S)-epoxy-
CC         (5Z,9E,14Z)-eicosatrienoate as substrate
CC         {ECO:0000269|PubMed:21217101};
CC         Vmax=550 nmol/min/mg enzyme with 10-hydroxy-(11S,12S)-
CC         epoxy- (5Z,8Z,14Z)-eicosatrienoate as substrate
CC         {ECO:0000269|PubMed:21217101};
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Peroxisome.
CC   -!- INDUCTION: By compounds that cause peroxisome proliferation such as
CC       clofibrate, tiadenol and fenofibrate.
CC   -!- DOMAIN: The N-terminal domain has phosphatase activity. The C-terminal
CC       domain has epoxide hydrolase activity.
CC   -!- PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-
CC       prostaglandin-J2 is autocatalytic and reversible. It may occur as an
CC       alternative to other cysteine modifications, such as S-nitrosylation
CC       and S-palmitoylation (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the AB hydrolase superfamily. Epoxide hydrolase
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X65083; CAA46211.1; -; mRNA.
DR   EMBL; X60328; CAA42898.1; -; mRNA.
DR   PIR; A47503; A47503.
DR   RefSeq; NP_075225.1; NM_022936.1.
DR   AlphaFoldDB; P80299; -.
DR   SMR; P80299; -.
DR   STRING; 10116.ENSRNOP00000023385; -.
DR   BindingDB; P80299; -.
DR   ChEMBL; CHEMBL5669; -.
DR   DrugCentral; P80299; -.
DR   GuidetoPHARMACOLOGY; 2970; -.
DR   SwissLipids; SLP:000001643; -.
DR   ESTHER; ratno-hyes; Epoxide_hydrolase.
DR   MEROPS; S33.973; -.
DR   CarbonylDB; P80299; -.
DR   iPTMnet; P80299; -.
DR   PhosphoSitePlus; P80299; -.
DR   PaxDb; 10116-ENSRNOP00000023385; -.
DR   Ensembl; ENSRNOT00055010957; ENSRNOP00055008541; ENSRNOG00055006699.
DR   Ensembl; ENSRNOT00055010964; ENSRNOP00055008548; ENSRNOG00055006699.
DR   Ensembl; ENSRNOT00060018220; ENSRNOP00060014181; ENSRNOG00060010710.
DR   Ensembl; ENSRNOT00060018225; ENSRNOP00060014186; ENSRNOG00060010710.
DR   GeneID; 65030; -.
DR   KEGG; rno:65030; -.
DR   UCSC; RGD:620732; rat.
DR   AGR; RGD:620732; -.
DR   CTD; 2053; -.
DR   RGD; 620732; Ephx2.
DR   eggNOG; KOG3085; Eukaryota.
DR   eggNOG; KOG4178; Eukaryota.
DR   InParanoid; P80299; -.
DR   OrthoDB; 2443908at2759; -.
DR   PhylomeDB; P80299; -.
DR   BRENDA; 3.3.2.10; 5301.
DR   Reactome; R-RNO-2142670; Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET).
DR   Reactome; R-RNO-9018682; Biosynthesis of maresins.
DR   Reactome; R-RNO-9033241; Peroxisomal protein import.
DR   SABIO-RK; P80299; -.
DR   PRO; PR:P80299; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0005777; C:peroxisome; IDA:RGD.
DR   GO; GO:0033885; F:10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004301; F:epoxide hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0042577; F:lipid phosphatase activity; ISS:UniProtKB.
DR   GO; GO:0052642; F:lysophosphatidic acid phosphatase activity; ISS:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IMP:RGD.
DR   GO; GO:0016791; F:phosphatase activity; IDA:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0015643; F:toxic substance binding; ISO:RGD.
DR   GO; GO:0042632; P:cholesterol homeostasis; ISO:RGD.
DR   GO; GO:0097176; P:epoxide metabolic process; IDA:UniProtKB.
DR   GO; GO:0043651; P:linoleic acid metabolic process; IMP:RGD.
DR   GO; GO:0046839; P:phospholipid dephosphorylation; ISS:UniProtKB.
DR   GO; GO:0045777; P:positive regulation of blood pressure; IMP:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0002539; P:prostaglandin production involved in inflammatory response; IMP:RGD.
DR   GO; GO:0090181; P:regulation of cholesterol metabolic process; ISO:RGD.
DR   GO; GO:1904681; P:response to 3-methylcholanthrene; IEP:RGD.
DR   GO; GO:0009636; P:response to toxic substance; IEA:UniProtKB-KW.
DR   GO; GO:0046272; P:stilbene catabolic process; ISO:RGD.
DR   CDD; cd02603; HAD_sEH-N_like; 1.
DR   Gene3D; 3.40.50.1820; alpha/beta hydrolase; 1.
DR   Gene3D; 3.40.50.1000; HAD superfamily/HAD-like; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR000073; AB_hydrolase_1.
DR   InterPro; IPR000639; Epox_hydrolase-like.
DR   InterPro; IPR036412; HAD-like_sf.
DR   InterPro; IPR006439; HAD-SF_hydro_IA.
DR   InterPro; IPR011945; HAD-SF_ppase_IA/epoxid_hydro_N.
DR   InterPro; IPR023214; HAD_sf.
DR   InterPro; IPR023198; PGP-like_dom2.
DR   NCBIfam; TIGR02247; HAD-1A3-hyp; 1.
DR   NCBIfam; TIGR01509; HAD-SF-IA-v3; 1.
DR   PANTHER; PTHR43329:SF4; BIFUNCTIONAL EPOXIDE HYDROLASE 2; 1.
DR   PANTHER; PTHR43329; EPOXIDE HYDROLASE; 1.
DR   Pfam; PF00561; Abhydrolase_1; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00111; ABHYDROLASE.
DR   PRINTS; PR00412; EPOXHYDRLASE.
DR   SFLD; SFLDG01130; C1.5.1:_Epoxide_Hydrolase_Phos; 1.
DR   SFLD; SFLDS00003; Haloacid_Dehalogenase; 1.
DR   SUPFAM; SSF53474; alpha/beta-Hydrolases; 1.
DR   SUPFAM; SSF56784; HAD-like; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Aromatic hydrocarbons catabolism; Cytoplasm; Detoxification;
KW   Direct protein sequencing; Hydrolase; Lipid metabolism; Lipoprotein;
KW   Magnesium; Metal-binding; Multifunctional enzyme; Peroxisome;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN           1..554
FT                   /note="Bifunctional epoxide hydrolase 2"
FT                   /id="PRO_0000084114"
FT   DOMAIN          257..530
FT                   /note="AB hydrolase-1"
FT                   /evidence="ECO:0000255"
FT   REGION          1..224
FT                   /note="Phosphatase"
FT   REGION          233..554
FT                   /note="Epoxide hydrolase"
FT   MOTIF           552..554
FT                   /note="Microbody targeting signal"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        333
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   ACT_SITE        465
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250|UniProtKB:P34913"
FT   ACT_SITE        523
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   BINDING         9
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250|UniProtKB:P34913"
FT   BINDING         11
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250|UniProtKB:P34913"
FT   BINDING         123..124
FT                   /ligand="phosphate"
FT                   /ligand_id="ChEBI:CHEBI:43474"
FT                   /evidence="ECO:0000250|UniProtKB:P34913"
FT   BINDING         185
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250|UniProtKB:P34913"
FT   BINDING         381
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P34913"
FT   MOD_RES         55
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P34914"
FT   MOD_RES         176
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P34914"
FT   MOD_RES         176
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P34914"
FT   MOD_RES         191
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P34914"
FT   MOD_RES         215
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P34914"
FT   MOD_RES         368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P34914"
FT   MOD_RES         420
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P34914"
FT   MOD_RES         454
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P34914"
FT   MOD_RES         504
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P34914"
FT   MOD_RES         553
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P34914"
FT   LIPID           521
FT                   /note="S-(15-deoxy-Delta12,14-prostaglandin J2-9-
FT                   yl)cysteine"
FT                   /evidence="ECO:0000250"
FT   MUTAGEN         332
FT                   /note="H->Q: Reduces epoxide hydrolase activity by 95%."
FT   MUTAGEN         333
FT                   /note="D->G: Loss of epoxide hydrolase activity."
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   MUTAGEN         334
FT                   /note="W->F: Slight reduction of epoxide hydrolase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   MUTAGEN         433
FT                   /note="E->Q,K: Slight loss of epoxide hydrolase activity."
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   MUTAGEN         434
FT                   /note="D->Y: Slight loss of epoxide hydrolase activity."
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   MUTAGEN         493
FT                   /note="E->Q,K: No effect."
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   MUTAGEN         495
FT                   /note="D->H: Loss of epoxide hydrolase activity."
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   MUTAGEN         517
FT                   /note="H->Y: Reduces epoxide hydrolase activity by 50%.
FT                   Loss of activity; when associated with Y-521."
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   MUTAGEN         521
FT                   /note="C->Y: Loss of epoxide hydrolase activity; when
FT                   associated with Y-517."
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   MUTAGEN         523
FT                   /note="H->D,N,Y: Loss of epoxide hydrolase activity."
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   MUTAGEN         526
FT                   /note="Q->H: Reduces epoxide hydrolase activity by 80%;
FT                   when associated with T-542."
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   MUTAGEN         540
FT                   /note="W->L,S: Reduces epoxide hydrolase activity by 95%."
FT                   /evidence="ECO:0000269|PubMed:8626766"
FT   MUTAGEN         542
FT                   /note="K->T: Reduces epoxide hydrolase activity by 80%;
FT                   when associated with H-526."
FT                   /evidence="ECO:0000269|PubMed:8626766"
SQ   SEQUENCE   554 AA;  62340 MW;  145FDCA53F582138 CRC64;
     MALRVAAFDL DGVLALPSIA GVLRHTEEAL ALPRDFLLGA FQMKFPEGPT EQLMKGKITF
     SQWVPLMDES CRKSSKACGA SLPENFSISE IFSQAMAARS INRPMLQAAA ALKKKGFTTC
     IVTNNWLDDS DKRDILAQMM CELSQHFDFL IESCQVGMIK PEPQIYKFVL DTLKAKPNEV
     VFLDDFGSNL KPARDMGMVT ILVRDTASAL RELEKVTGTQ FPEAPLPVPC SPNDVSHGYV
     TVKPGIRLHF VEMGSGPAIC LCHGFPESWF SWRYQIPALA QAGFRVLAID MKGYGDSSSP
     PEIEEYAMEL LCEEMVTFLN KLGIPQAVFI GHDWAGVLVW NMALFHPERV RAVASLNTPL
     MPPNPEVSPM EVIRSIPVFN YQLYFQEPGV AEAELEKNMS RTFKSFFRTS DDMGLLTVNK
     ATEMGGILVG TPEDPKVSKI TTEEEIEYYI QQFKKSGFRG PLNWYRNTER NWKWSCKALG
     RKILVPALMV TAEKDIVLRP EMSKNMENWI PFLKRGHIED CGHWTQIEKP AEVNQILIKW
     LKTEIQNPSV TSKI
//
